Study of BI 1815368 for diabetic macular edema
Treatments studied
Part of Eyes & vision clinical trials.
This study tests a new medicine, BI 1815368, to see if it can help people with diabetic macular edema, a condition that causes swelling in the back of the eye and can blur vision. If you qualify, you may be able to try this treatment and help researchers learn if it works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have diabetes (type 1 or type 2) and your blood sugar levels are stable (HbA1c less than 12%) for at least 30 days.
- You have diabetic macular edema that involves the center of the retina (confirmed by an eye scan) with a certain thickness.
- Your vision in the study eye is between 20/32 and 20/320 (on an eye chart).
- You have not had certain eye treatments recently, like anti-VEGF injections within the last 8 weeks (or 16 weeks for some medicines), or other specified eye surgeries or steroids.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial tests MS-553 to see how it works and how safely it can be given to people with diabetic retinopathy causing central macular swelling (macular edema). You may be considered if your vision and eye scan results match, and if you can follow frequent study visits.
This trial tests if a new medicine (MK-8748) works as well as or better than the usual treatment (aflibercept) for people with diabetic macular edema, a condition that causes vision loss from diabetes-related swelling in the back of the eye.
This study tests different doses of a new medicine (BI 3812465) injected into the eye to treat diabetic macular edema—swelling in the back of the eye caused by diabetes that can blur vision. The trial measures how safe the medicine is and how well patients tolerate it.
This study tests an investigational drug called BI 764524 for people with moderate to severe diabetic retinopathy, a complication of diabetes that can damage the retina. The goal is to see if the treatment can help prevent vision loss.
This study tests a new drug (RO7823653) given as an eye injection for people with diabetic macular edema, a condition where swelling in the retina harms vision. It aims to see if the drug is safe and how the body processes it.
This trial tests a new medication, CU06-1004, for people with diabetic macular edema, a condition that causes blurry vision due to fluid buildup in the central part of the retina. The goal is to see if this drug can reduce the swelling and improve vision.
Hear when a new Macular Edema trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.